1.	General Evaluation
1.1	How would you rate this meeting? (1=Poor 10=Excellent)
	1   2   3   4   5   6   7   8   9   10
1.2	Did this meeting meet your expectations?      yes     no
1.3	Did this program prove useful to your work?
	extremely     somewhat     very little      not at all
1.4	Do you have any suggestions for next year’s meeting?
1.5	Overall comments
2.	Plenary Sessions
2.1	How would you rate the First Plenary Session? (1=Poor 10=Excellent)
	1   2   3   4   5   6   7   8   9   10
2.2	How would you rate the Second Plenary Session? (1=Poor 10=Excellent)
	1   2   3   4   5   6   7   8   9   10
2.3	How would you rate the Third Plenary Session? (1=Poor 10=Excellent)
	1   2   3   4   5   6   7   8   9   10
2.4	Do you have any suggestions for next year’s Plenary Sessions topics?
2.5	Comments on the Plenary Sessions
3.	Issues Panels
	How would you rate the Issues Panels? (1=Poor 10=Excellent)
3.1	EFFECT OF SECTION 1013 "RESEARCH ON OUTCOMES OF HEALTH CARE ITEMS AND SERVICES" OF THE US MEDICARE MODERNIZATION ACT ON OUTCOMES RESEARCH
	1   2    3    4   5   6   7   8   9    10
3.2	STRATIFIED COST-EFFECTIVENESS ANALYSIS: THE RISKS AND REWARD OF LOOKING AT SUB-GROUPS
	1   2    3    4   5   6   7   8   9    10
3.3	RISK SHARING DEALS IN THE REAL WORLD: CAN WE AFFORD THEM AND DO THEY WORK?
	1   2    3    4   5   6   7   8   9    10
3.4	COST ATTRIBUTION IN ECONOMIC EVALUATION: WHAT IS SIGNAL AND WHAT IS NOISE?
	1   2    3    4   5   6   7   8   9    10
3.5	INDUSTRY AND REGULATORY PERSPECTIVES ON TRANSLATING PATIENT REPORTED OUTCOME MEASURES.
	1   2    3    4   5   6   7   8   9    10
3.6	THE IMPACT OF MEDICARE’S PRESCRIPTION DRUG LEGISLATION ON PHARMACOECONOMICS AND OUTCOMES RESEARCH.
	1   2    3    4   5   6   7   8   9    10
3.7	THE VALUE OF POST-LAUNCH STUDIES – WHAT IS DESIRABLE VS. WHAT IS FEASIBLE?
	1   2    3    4   5   6   7   8   9    10
3.8	COST INFORMATION TREATMENT IN STATED PREFERENCE EXPERIMENTS – WHAT IS THE GOLD STANDARD?
	1   2    3    4   5   6   7   8   9    10
3.9	CAN WE BRIDGE TOO FAR? ISSUES IN MAPPING BETWEEN QUALITY-OF-LIFE INSTRUMENTS AND UTILITY.
	1   2    3    4   5   6   7   8   9    10
3.10	Do you have any suggestions for future Issues Panel topics
3.11	Comments on the Issues Panels
4.	Podium Presentations
4.1	In general, how would you rate the Podium Presentations? (1=Poor 10=Excellent)
	1   2   3   4   5   6   7   8   9   10
4.2	Were the speakers knowledgeable on their topics?	yes       no
4.3	Were there handouts/printed materials available?	yes       no
4.4	Were the visual presentations clear and easy to read?	yes       no
4.5	Please list any comments regarding Podium Presentations
5.	Poster Presentations
5.1	In general, how would you rate the Poster Presentations? (1=Poor 10=Excellent)
	1   2   3   4   6   7   8   9   100
5.2	Were there handouts/printed materials available?	yes       no
5.3	Were the visual presentations clear and easy to read?	yes       no
5.4	Please list any comments regarding Poster Presentations
6.	Workshop Presentations
6.1	In general, how would you rate the Workshop Presentations? (1=Poor 10=Excellent)
	1   2   3   4   5   6   7   8   9   10
6.2	Were speakers knowledgeable on their topics?	yes        no
6.3	Were there handouts/printed materials available?	yes        no
6.4	Were the visual presentations clear and easy to read?	yes        no
6.5	Which workshops did you attend (please use session codes)?
	WW1   WW2   WW3   WW4   WW5   WW6   WW8   WW9   WW10   WW11   WW12   WW13   WW14   WW15   WW16   WW17  WW18   WW19   WW20   WW21   WW22   WW23   WW24
6.6	Please list any comments regarding Workshop Presentations
7.	Program Personal Scheduler
7.1	Did you use the Online Personal Scheduler?	yes       noo
7.2	Was it useful?	yes       noo
7.3	Please list any suggestions regarding the Program Personal Scheduler
8.	Exhibition
8.1	How would you rate the exhibits? (1=poor 5=excellent)
	1     2     3     4     5
8.2	Were the exhibit hours long enough? (1=too short 5=too long)
	1     2     3     4     5
9.	ISPOR Professional Recruitment Assistance Program (PRAP) Center
9.1	Was the PRAP Center useful? (1=not useful at all 5=very useful)
	1   2   3  4  5   N/A
10.	Meeting  Management
10.1	Was the meeting well run? (1=poor 5=excellent)
	1     2     3     4     5
10.2	Was the printed program clear and easy to follow? (1=poor 5=excellent)
	1     2     3     4     5
11.	Future ISPOR Congress and Meeting
11.1	Do you plan to attend the ISPOR Seventh Annual European Congress to be held 24-26 October, 2004 in Hamburg, Germany?
	yes      no      not sure
11.2	Do you plan to attend the ISPOR Tenth Annual International Meeting to be held May 15-18, 2005 in Washington DC?
	yes      no      not sure
12.	Participant Information
12.1	Are you a:
	Registrant  Contributed paper presenter Media representative Exhibitor Other
12.2	What type of organization do you represent?
	Academic institution Hospital/medical Center Managed care organization Contract research organization Pharmaceutical company Diagnostic equipment manufacturer Consulting firm Pharmacy benefits management Government agency Other ( please specify)
12.3	How long have you been working in the field of pharmacoeconomics and outcomes research?
	less than 1 year 1-2 years 2-5 years 5-10 years 10-15 years 15-20 years more than 20 years
12.4	How many ISPOR Annual meetings have you attended before this one?
	none    1     2     3     4      6     7    8
12.5	How did you first hear of this meeting?
	ISPOR Connections Conference Mailing Colleague Other  ( please specify)
12.6	Do you have any comments or suggestions for the ISPOR Tenth Annual International Meeting?